Correspondence 0001628280-24-015354 from Mineralys Therapeutics, Inc. (MLYS) (CIK 0001933414) (MLYS)
Mineralys Therapeutics, Inc. (MLYS) (CIK 0001933414)
Date: April 9, 2024 · CIK: 0001933414 · Accession: 0001628280-24-015354
AI Filing Summary & Sentiment
File numbers found in text: 333-278122
Letter
Document
Mineralys Therapeutics, Inc.
150 N. Radnor Chester Road
Suite F200
Radnor, Pennsylvania 19087
April 9, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Mineralys Therapeutics, Inc.
Registration Statement on Form S-3, as amended
File No. 333-278122
Ladies and Gentlemen:
Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of Mineralys Therapeutics, Inc., respectfully requests that the effective date of the Registration Statement on Form S-3 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on April 11, 2024, or as soon as practicable thereafter.
If you have any questions or require additional information, please contact Jonathan R. Zimmerman of Faegre Drinker Biddle & Reath LLP at (612) 766-8419. Thank you for your assistance and cooperation in this matter.
Very truly yours,
MINERALYS THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm Document Mineralys Therapeutics, Inc. 150 N. Radnor Chester Road Suite F200 Radnor, Pennsylvania 19087 April 9, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Mineralys Therapeutics, Inc. Registration Statement on Form S-3, as amended File No. 333-278122 Ladies and Gentlemen: Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of Mineralys Therapeutics, Inc., respectfully requests that the effective date of the Registration Statement on Form S-3 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on April 11, 2024, or as soon as practicable thereafter. If you have any questions or require additional information, please contact Jonathan R. Zimmerman of Faegre Drinker Biddle & Reath LLP at (612) 766-8419. Thank you for your assistance and cooperation in this matter. Very truly yours, MINERALYS THERAPEUTICS, INC. By: /s/ Adam Levy Adam Levy Chief Financial Officer cc: Jon Congleton, Chief Executive Officer, Mineralys Therapeutics, Inc. Jonathan R. Zimmerman, Faegre Drinker Biddle & Reath LLP Griffin D. Foster, Faegre Drinker Biddle & Reath LLP Ilir Mujalovic, Shearman & Sterling LLP